Square Pharmaceuticals PLC. (DSE: SQURPHARMA)

DSE: SQURPHARMA Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	70,037	70,101	60,708	57,598	50,703	45,876
Revenue Growth (YoY)	8.60%	15.47%	5.40%	13.60%	10.52%	4.19%
Cost of Revenue	38,153	37,957	32,473	28,719	25,470	23,141
Gross Profit	31,884	32,144	28,235	28,879	25,233	22,736
Selling, General & Admin	14,755	14,168	11,689	12,118	10,034	8,855
Other Operating Expenses	-204.58	-199.9	-144.4	-98.27	-69.57	10.79
Operating Expenses	14,551	13,968	11,545	12,019	9,965	8,865
Operating Income	17,333	18,176	16,690	16,860	15,269	13,870
Interest Expense	-271.39	-244	-118.97	-0.03	-0.01	-0.11
Interest & Investment Income	5,027	4,651	3,957	3,004	3,137	2,965
Earnings From Equity Investments	2,803	2,595	2,523	2,011	1,291	586.24
Currency Exchange Gain (Loss)	430.32	346.52	650.1	451.34	19.42	-0.7
Other Non Operating Income (Expenses)	-	-	-	-	34.43	33.62
EBT Excluding Unusual Items	25,323	25,524	23,701	22,325	19,751	17,455
Gain (Loss) on Sale of Investments	-	-	-	384.59	177.04	100.09
Gain (Loss) on Sale of Assets	-203.85	-208	-79.8	53.49	-	28.38
Other Unusual Items	0.26	0.26	0.62	0.72	32.06	-
Pretax Income	25,119	25,316	23,622	22,764	19,960	17,583
Income Tax Expense	4,100	4,389	4,642	4,607	4,013	4,229
Earnings From Continuing Operations	21,019	20,927	18,980	18,157	15,947	13,354
Minority Interest in Earnings	-2.01	-1.61	-0.24	0.03	-	-
Net Income	21,017	20,926	18,980	18,157	15,947	13,354
Net Income to Common	21,017	20,926	18,980	18,157	15,947	13,354
Net Income Growth	7.89%	10.25%	4.53%	13.86%	19.42%	5.60%
Shares Outstanding (Basic)	886	886	886	886	886	886
Shares Outstanding (Diluted)	886	886	886	886	886	886
Shares Change (YoY)	-	-	-	-	-	-0.00%
EPS (Basic)	23.71	23.61	21.41	20.48	17.99	15.06
EPS (Diluted)	23.71	23.61	21.41	20.48	17.99	15.06
EPS Growth	7.89%	10.25%	4.53%	13.86%	19.42%	5.60%
Free Cash Flow	8,105	14,348	5,685	6,692	7,178	8,718
Free Cash Flow Per Share	9.14	16.19	6.41	7.55	8.10	9.83
Dividend Per Share	11.000	11.000	10.500	10.000	6.000	4.476
Dividend Growth	4.76%	4.76%	5.00%	66.67%	34.04%	19.74%
Gross Margin	45.52%	45.85%	46.51%	50.14%	49.77%	49.56%
Operating Margin	24.75%	25.93%	27.49%	29.27%	30.11%	30.23%
Profit Margin	30.01%	29.85%	31.26%	31.52%	31.45%	29.11%
Free Cash Flow Margin	11.57%	20.47%	9.36%	11.62%	14.16%	19.00%
EBITDA	19,612	20,495	19,000	18,695	17,151	15,791
EBITDA Margin	28.00%	29.24%	31.30%	32.46%	33.83%	34.42%
D&A For EBITDA	2,279	2,319	2,310	1,835	1,882	1,921
EBIT	17,333	18,176	16,690	16,860	15,269	13,870
EBIT Margin	24.75%	25.93%	27.49%	29.27%	30.11%	30.23%
Effective Tax Rate	16.32%	17.34%	19.65%	20.24%	20.10%	24.05%
Revenue as Reported	-	-	-	57,598	50,703	45,876
Advertising Expenses	-	1,355	961.42	3.61	3.01	8.7

Source: S&P Capital IQ. Standard template. Financial Sources.